Tomas Hajek1, Cynthia Calkin2, Ryan Blagdon2, Claire Slaney2, Martin Alda3. 1. Department of Psychiatry (TH, CC, RB, CS, MA), Dalhousie University, Halifax, Nova Scotia, Canada; Prague Psychiatric Center (TH, MA), Department of Psychiatry and Medical Psychology, 3rd School of Medicine, Charles University, Prague, Czech Republic. Electronic address: tomas.hajek@dal.ca. 2. Department of Psychiatry (TH, CC, RB, CS, MA), Dalhousie University, Halifax, Nova Scotia, Canada. 3. Department of Psychiatry (TH, CC, RB, CS, MA), Dalhousie University, Halifax, Nova Scotia, Canada; Prague Psychiatric Center (TH, MA), Department of Psychiatry and Medical Psychology, 3rd School of Medicine, Charles University, Prague, Czech Republic.
Abstract
BACKGROUND: Neuroimaging changes in bipolar disorder (BD) may be secondary to the presence of certain clinical factors. Type 2 diabetes mellitus (T2DM) damages the brain and frequently co-occurs with BD. Studying patients with both T2DM and BD could help identify preventable risk factors for neuroimaging changes in BD. METHODS: We used 1.5T magnetic resonance spectroscopy to measure prefrontal N-acetylaspartate (NAA), which is mainly localized in neurons, and total creatine (tCr), an energy metabolite, in 19 BD patients with insulin resistance/glucose intolerance (BD + IR/GI), 14 BD subjects with T2DM (BD + T2DM), 15 euglycemic BD participants, and 11 euglycemic, nonpsychiatric control. RESULTS: The levels of NAA and tCr were lowest among BD + T2DM, intermediate in the BD + IR/GI, and highest among the euglycemic BD and control subjects (F₃,₅₅ = 4.57, p = .006; F₃,₅₅ = 2.92, p = .04, respectively). Even the BD + IR/GI subjects had lower NAA than the euglycemic participants (t₄₃ = 2.13, p = .04). Total Cr was associated with NAA (β = .52, t₅₆ = 5.57, p = .000001). Both NAA and tCr correlated with Global Assessment of Functioning scores (r₄₆ = .28, p = .05; r₄₆ = .48, p = .0004, respectively). CONCLUSIONS: T2DM, but also prediabetes, may be risk factors for prefrontal neurochemical alterations in BD. These changes were associated with poor psychosocial functioning and could indicate impaired energy metabolism. The findings emphasize the importance of improving diabetes care in BD and suggest potential options for treatment of neuroimaging alterations.
BACKGROUND: Neuroimaging changes in bipolar disorder (BD) may be secondary to the presence of certain clinical factors. Type 2 diabetes mellitus (T2DM) damages the brain and frequently co-occurs with BD. Studying patients with both T2DM and BD could help identify preventable risk factors for neuroimaging changes in BD. METHODS: We used 1.5T magnetic resonance spectroscopy to measure prefrontal N-acetylaspartate (NAA), which is mainly localized in neurons, and total creatine (tCr), an energy metabolite, in 19 BD patients with insulin resistance/glucose intolerance (BD + IR/GI), 14 BD subjects with T2DM (BD + T2DM), 15 euglycemic BD participants, and 11 euglycemic, nonpsychiatric control. RESULTS: The levels of NAA and tCr were lowest among BD + T2DM, intermediate in the BD + IR/GI, and highest among the euglycemic BD and control subjects (F₃,₅₅ = 4.57, p = .006; F₃,₅₅ = 2.92, p = .04, respectively). Even the BD + IR/GI subjects had lower NAA than the euglycemic participants (t₄₃ = 2.13, p = .04). Total Cr was associated with NAA (β = .52, t₅₆ = 5.57, p = .000001). Both NAA and tCr correlated with Global Assessment of Functioning scores (r₄₆ = .28, p = .05; r₄₆ = .48, p = .0004, respectively). CONCLUSIONS: T2DM, but also prediabetes, may be risk factors for prefrontal neurochemical alterations in BD. These changes were associated with poor psychosocial functioning and could indicate impaired energy metabolism. The findings emphasize the importance of improving diabetes care in BD and suggest potential options for treatment of neuroimaging alterations.
Authors: Rafael T de Sousa; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji Journal: Expert Opin Ther Targets Date: 2014-07-24 Impact factor: 6.902
Authors: Orestes V Forlenza; Artur Martins Novaes Coutinho; Ivan Aprahamian; Silvana Prando; Luciana Lucas Mendes; Breno S Diniz; Wagner F Gattaz; Carlos A Buchpiguel Journal: ACS Chem Neurosci Date: 2014-04-29 Impact factor: 4.418
Authors: Tomas Hajek; Cynthia Calkin; Ryan Blagdon; Claire Slaney; Rudolf Uher; Martin Alda Journal: Neuropsychopharmacology Date: 2014-06-19 Impact factor: 7.853
Authors: Rodrigo B Mansur; Francheska Delgado-Peraza; Mehala Subramaniapillai; Yena Lee; Michelle Iacobucci; Flora Nasri; Nelson Rodrigues; Joshua D Rosenblat; Elisa Brietzke; Victoria E Cosgrove; Nicole E Kramer; Trisha Suppes; Charles L Raison; Andrea Fagiolini; Natalie Rasgon; Sahil Chawla; Carlos Nogueras-Ortiz; Dimitrios Kapogiannis; Roger S McIntyre Journal: J Psychiatr Res Date: 2020-12-04 Impact factor: 4.791